ATE458753T1 - Methoden der verhinderung und behandlung der alzheimer'schen krankheit - Google Patents

Methoden der verhinderung und behandlung der alzheimer'schen krankheit

Info

Publication number
ATE458753T1
ATE458753T1 AT04701585T AT04701585T ATE458753T1 AT E458753 T1 ATE458753 T1 AT E458753T1 AT 04701585 T AT04701585 T AT 04701585T AT 04701585 T AT04701585 T AT 04701585T AT E458753 T1 ATE458753 T1 AT E458753T1
Authority
AT
Austria
Prior art keywords
alzheimer
disease
prevention
treatment
methods
Prior art date
Application number
AT04701585T
Other languages
English (en)
Inventor
Frank Mattner
Original Assignee
Affiris Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris Ag filed Critical Affiris Ag
Application granted granted Critical
Publication of ATE458753T1 publication Critical patent/ATE458753T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
AT04701585T 2003-01-14 2004-01-13 Methoden der verhinderung und behandlung der alzheimer'schen krankheit ATE458753T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT362003 2003-01-14
AT0146403A AT413945B (de) 2003-01-14 2003-09-17 Impfstoff für die alzheimer-krankheit
PCT/EP2004/000162 WO2004062556A2 (en) 2003-01-14 2004-01-13 Methods for preventing and treating alzheimer’s disease (ad)

Publications (1)

Publication Number Publication Date
ATE458753T1 true ATE458753T1 (de) 2010-03-15

Family

ID=32714004

Family Applications (3)

Application Number Title Priority Date Filing Date
AT0146403A AT413945B (de) 2003-01-14 2003-09-17 Impfstoff für die alzheimer-krankheit
AT04701585T ATE458753T1 (de) 2003-01-14 2004-01-13 Methoden der verhinderung und behandlung der alzheimer'schen krankheit
AT05107898T ATE376559T1 (de) 2003-01-14 2004-01-13 Methoden der verhinderung und behandlung der alzheimer'schen krankheit

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT0146403A AT413945B (de) 2003-01-14 2003-09-17 Impfstoff für die alzheimer-krankheit

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT05107898T ATE376559T1 (de) 2003-01-14 2004-01-13 Methoden der verhinderung und behandlung der alzheimer'schen krankheit

Country Status (14)

Country Link
US (2) US7732568B2 (de)
EP (2) EP1583774B1 (de)
JP (2) JP4547373B2 (de)
CN (2) CN102526699A (de)
AT (3) AT413945B (de)
CA (1) CA2513218C (de)
CY (2) CY1107146T1 (de)
DE (2) DE602004025668D1 (de)
DK (2) DK1679319T3 (de)
ES (2) ES2339447T3 (de)
PL (1) PL209989B1 (de)
PT (2) PT1583774E (de)
SI (1) SI1583774T1 (de)
WO (1) WO2004062556A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003303198A1 (en) 2002-12-19 2004-07-14 New York University Method for treating amyloid disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
AT413336B (de) * 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
JP2007522119A (ja) * 2004-01-28 2007-08-09 キュリックス エーピーエス アミロイド関連疾患用ワクチンとしてのアミロイドタンパク質のコンジュゲート
AT413946B (de) 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
AT500483B1 (de) 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
NZ568012A (en) * 2005-12-12 2012-07-27 Ac Immune Sa A beta 1-42 specific monoclonal antibodies with therapeutic properties
EP1878747A1 (de) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-hergestellte Antikörper
RU2498999C2 (ru) * 2006-07-14 2013-11-20 Ац Иммуне Са Гуманизированное антитело к амилоиду бета
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
HRP20150086T1 (xx) * 2007-06-12 2015-02-27 Ac Immune S.A. Humanizirana antitijela za beta amiloid
CA2701788C (en) * 2007-10-05 2017-06-13 Genentech, Inc. Humanized beta-amyloid antibody for treating ocular diseases
PL2238166T3 (pl) * 2007-10-05 2014-07-31 Genentech Inc Zastosowanie przeciwciała anty-Beta amyloidowego w chorobach oczu
AU2008311366B2 (en) * 2007-10-05 2015-03-12 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
WO2009054537A1 (ja) 2007-10-25 2009-04-30 Kagoshima University アミロイドβペプチドのミミック分子を用いたペプチドワクチン
CN104098695B (zh) * 2007-10-29 2018-09-07 道健康生活医药株式会社 抗体及其应用
WO2009128948A1 (en) 2008-04-17 2009-10-22 Peptimmune, Inc. Design and synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
CA2723995A1 (en) * 2008-06-12 2009-12-17 Affiris Ag Compounds for treating symptoms associated with parkinson's disease
AT506820B1 (de) * 2008-06-12 2011-07-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzine gegen alzheimer-krankheit
AT506819B1 (de) * 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US20120328605A1 (en) * 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
RS53496B1 (sr) 2011-10-04 2015-02-27 Affiris Ag POSTUPAK ZA DETEKCIJU Aβ-SPECIFIČNIH ANTITELA U BIOLOŠKOM UZORKU
EP2787347A1 (de) 2013-04-03 2014-10-08 Affiris AG Verfahren zur Erkennung von Aß-spezifischen Antikörpern in einer biologischen Probe
US10381614B2 (en) * 2013-04-17 2019-08-13 Samsung Sdi Co., Ltd. Battery module
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
CA3003943A1 (en) 2015-11-03 2017-05-11 Affiris Ag Method for vaccination against a self-antigen in a human patient
CN105237628B (zh) * 2015-11-17 2018-08-07 南开大学 一种用于治疗阿尔兹海默症的多肽
CN107022019B (zh) * 2016-11-24 2020-10-30 桂林医学院 一种用于脑内降铁除自由基的多肽、制备方法与应用
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
CN119136838A (zh) 2022-02-28 2024-12-13 特瑞德姆生物科技有限责任两合公司 由至少一种β-葡聚糖或甘露聚糖组成或包含至少一种β-葡聚糖或甘露聚糖的偶联物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) * 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US5650489A (en) * 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
GB9022190D0 (en) 1990-10-12 1990-11-28 Perham Richard N Immunogenic material
US5639603A (en) * 1991-09-18 1997-06-17 Affymax Technologies N.V. Synthesizing and screening molecular diversity
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6088993A (en) 1999-02-05 2000-07-18 Irace; Francisco D. Closure system
WO2000050077A1 (en) 1999-02-25 2000-08-31 Smithkline Beecham Biologicals S.A. Immunogens comprising a peptide and a carrier derived from h.influenzae protein d
US6703491B1 (en) * 1999-03-17 2004-03-09 Exelixis, Inc. Drosophila sequences
JP2003509020A (ja) * 1999-09-03 2003-03-11 ラモット・ユニバーシティ・オーソリティ・フォー・アプライド・リサーチ・アンド・インダストリアル・ディベロップメント・リミテッド プラーク形成疾患の診断、治療、予防に有用な薬剤、組成物、その使用法
ES2219517T3 (es) 2000-03-03 2004-12-01 Glaxosmithkline Biologicals S.A. Vacuna para el tratamiento de la aterosclerosis.
GB0024200D0 (en) * 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
ES2276732T3 (es) 2001-09-03 2007-07-01 Bio Life Science Forschungs- Und Entwicklungsges.M.B.H. Mimotopos de antigenos y vacuna contra enfermedades cancerosas.
ATE345504T1 (de) * 2002-05-07 2006-12-15 Pasteur Institut Screeningverfahren für peptide, die die bindung von pp1c an bcl-2, bcl-xl und bcl-w proteine inhibieren

Also Published As

Publication number Publication date
DK1583774T3 (da) 2010-05-03
ATA14642003A (de) 2005-11-15
WO2004062556A3 (en) 2004-09-16
CN1826354B (zh) 2014-01-08
PT1679319E (pt) 2008-01-10
WO2004062556A2 (en) 2004-07-29
EP1679319A1 (de) 2006-07-12
SI1583774T1 (sl) 2010-06-30
JP2010174024A (ja) 2010-08-12
US20060111301A1 (en) 2006-05-25
CA2513218A1 (en) 2004-07-29
HK1091499A1 (en) 2007-01-19
CA2513218C (en) 2013-06-25
ES2296084T3 (es) 2008-04-16
JP5282058B2 (ja) 2013-09-04
DE602004009705D1 (de) 2007-12-06
ATE376559T1 (de) 2007-11-15
WO2004062556A8 (en) 2004-10-21
EP1583774A2 (de) 2005-10-12
AT413945B (de) 2006-07-15
PT1583774E (pt) 2010-04-07
CN102526699A (zh) 2012-07-04
AU2004204349A1 (en) 2004-07-29
EP1583774B1 (de) 2010-02-24
DE602004025668D1 (de) 2010-04-08
CY1110634T1 (el) 2015-04-29
JP2006515876A (ja) 2006-06-08
CN1826354A (zh) 2006-08-30
EP1679319B1 (de) 2007-10-24
CY1107146T1 (el) 2012-05-23
ES2339447T3 (es) 2010-05-20
PL378333A1 (pl) 2006-03-20
JP4547373B2 (ja) 2010-09-22
US20110015131A1 (en) 2011-01-20
ES2339447T8 (es) 2011-05-26
PL209989B1 (pl) 2011-11-30
US7732568B2 (en) 2010-06-08
DE602004009705T2 (de) 2008-06-05
DK1679319T3 (da) 2008-01-28

Similar Documents

Publication Publication Date Title
DE602004010407D1 (de) Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
ATE385794T1 (de) Benzothiazolderivate zur behandlung von alzheimer und parkinson
ES2414872T8 (es) Terapia combinada para la prevención o tratamiento de la enfermedad de Alzheimer y kit correspondiente
NO20054640D0 (no) Fremgangsmater for behandling av Parkinsons sykdom
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
EP1643986A4 (de) Phenylcarboxylat-beta-secretase-hemmer zur behandlung von morbus alzheimer
ATE350375T1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
ATE519488T1 (de) Aminopyrazin-analoga zur behandlung von glaukomen und anderen durch rho-kinase verursachten krankheiten
ATE417606T1 (de) Phenethanolamin-derivate zur behandlung von erkrankungen der atemwege
DE60216275D1 (de) Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer-krankheit
ATE535236T1 (de) Therapeutische strategien für die prävention und behandlung der alzheimer-krankheit
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE60318839D1 (de) 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
EP1732484A4 (de) Ophthalmisches implantat zur behandlung von glaukom
IS8135A (is) Þríhringtengdar indólafleiður og notkun þeirra til að meðhöndla Alzheimers-sjúkdóm
NO20053263L (no) Hydroksyetylaminderivater for behandling av Alzheimers sykdom.
DE602004029465D1 (de) Externes Präparat zur Behandlung von Fusspilz
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
EA200800880A1 (ru) Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
EP1416957A4 (de) Behandlung von immunerkrankungen und b-zellen-erkrankungen
DE60136748D1 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1583774

Country of ref document: EP